Edwards Lifesciences Pays Boston Scientific $180 Million to Settle Global Patent Disputes
Today Boston Scientific Corp. and Edwards Lifesciences Corp. announced their agreement to settle all outstanding patent disputes around the world. The companies have a past history of ongoing patent disputes surrounding various heart valve products. This agreement means all pending cases or appeals in courts and patent offices between Boston Scientific and Edwards will be dismissed. The companies will also forgo litigating the patent disputes related to current portfolios of transcatheter aortic valves, mitral valve repair devices and left atrial appendage closure devices. As a result of the agreement Edwards paid Boston Scientific $180 million. Other terms of the agreement are confidential.
Following the announcement on Tuesday morning, both companies enjoyed a boost during early trading on the stock market, with Edwards Lifesciences up 6% and Boston Scientific up 3.4%.
Related Articles
-
The Class I recall is a result of a mold overflow defect that could obstruct blood flow.
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
-
“We are pleased to expand our board of directors with two highly qualified executives from different sectors of the healthcare industry.”
-
The Inspiris Resilia valve is intended for aortic valve replacement.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.